Monitoring After Administration of Antihypertensive Medication

Clinical Monitoring Schedule

The American College of Cardiology recommends that patients who start or adjust antihypertensive therapy should be evaluated every month until blood pressure is controlled, then every 3-6 months thereafter 1
Follow-up visits every 4-6 weeks are required for dose titration and addition of medications until the target blood pressure is safely achieved, as recommended by the American Journal of Kidney Diseases 2, 1
Some guidelines recommend monthly evaluations for assessment of adherence and response to therapy, according to the American College of Cardiology 1
In children and adolescents with hypertension, follow-up every 4-6 weeks is required for dose adjustment until normal blood pressure is achieved, as stated in the Pediatrics journal 3

A comprehensive metabolic panel, including electrolytes, BUN, serum creatinine, fasting glucose, liver function, and TSH, should be performed before starting therapy, as recommended by the American Journal of Kidney Diseases 2
Urinalysis for screening of proteinuria and kidney disease is recommended, according to the American Journal of Kidney Diseases 2
Lipid profiling for cardiovascular risk stratification is recommended, as stated in the American Journal of Kidney Diseases 2
For RAS inhibitors (ACE inhibitors/ARBs) or diuretics, a basic metabolic panel should be checked within 2-4 weeks after starting or titrating therapy, as recommended by the American Journal of Kidney Diseases 2, 4, 5
The ACC/AHA 2017 guideline explicitly states to check electrolytes and kidney function 2-4 weeks after starting RAS inhibitors or diuretics, according to the Journal of the American College of Cardiology 4, 5

Home blood pressure monitoring (HBPM) should be used systematically to avoid hypotension (systolic blood pressure <110 mmHg) during drug titration, as recommended by the American Journal of Kidney Diseases 2, 1
HBPM helps detect white coat hypertension, masked hypertension, and helps achieve blood pressure targets, according to the Journal of the American College of Cardiology 1

Each follow-up visit should include an assessment of blood pressure control, as recommended by the American College of Cardiology 1
Evaluation of orthostatic hypotension in selected patients (e.g., elderly or with postural symptoms) is recommended, according to the Circulation journal 5
Assessment of medication side effects is recommended, as stated in the American Journal of Kidney Diseases 2
Adherence to medication and lifestyle therapy should be evaluated, according to the American College of Cardiology 1

In patients with chronic kidney disease (CKD), monitoring of kidney function is crucial during the first few weeks of therapy, especially with ACE inhibitors, as recommended by the American Journal of Kidney Diseases 2
In patients with stage 2 hypertension, immediate treatment and careful monitoring are required, and medication doses should be adjusted as needed, according to the Journal of the American College of Cardiology 4, 5
Consider initiating therapy with 2 agents from different classes for stage 2 hypertension, as recommended by the Journal of the American College of Cardiology 4, 5

Obtain a basic metabolic panel (electrolytes, creatinine) 2–4 weeks after initiating or adjusting the dose of an ACE inhibitor, ARB, or diuretic to detect hyper‑ or hypokalemia and acute kidney injury. 6

Perform an HbA1c or fasting‑glucose test before starting any antihypertensive medication to identify undiagnosed diabetes. 6

Re‑measure HbA1c every 3–6 months because blood‑pressure drugs can influence glucose metabolism. 6
Check a lipid profile 4–12 weeks after initiating or changing lipid‑lowering therapy, then annually, to maintain cardiovascular risk assessment. 6

An increase in serum creatinine up to 30 % from baseline is considered acceptable and does not require discontinuation of the antihypertensive agent. 6
Discontinue therapy if serum creatinine rises ≥100 %, estimated GFR falls below 20 mL/min/1.73 m², or serum potassium exceeds 5.5 mmol/L. 7

The risk of hyperkalemia rises substantially when ACE inhibitors/ARBs are combined with aldosterone antagonists or potassium‑sparing diuretics. [6][7]